Advanced or Metastatic Biliary Tract Cancer
Conditions
Keywords
MRG002, Antibody Drug Conjugate (ADC), HER2, Biliary Tract Cancer
Brief summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in HER2-positive unresectable locally advanced or metastatic biliary tract cancer patients who have progressed during or relapsed after at least one prior stand therapy.
Detailed description
The study consists of two stages. In Phase IIa, 25-31 eligible subjects will be enrolled to evaluate the safety and preliminary efficacy of MRG002. Based on the initial safety and efficacy data obtained from the Phase IIa, the study design of the second stage Phase IIb single-arm study either will be adjusted or the trial will be stopped. If the Phase IIa data support the continuation of the study, in the second stage, approximately an additional 55 subjects will be enrolled to further evaluate the efficacy and safety of MRG002.
Interventions
DRUGMRG002
Administrated intravenously
Sponsors
Shanghai Miracogen Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Willing to sign the ICF and follow the requirements specified in the protocol. 2. Aged 18 to 75 (including 18 and 75), both genders. 3. Expected survival time ≥ 12 weeks. 4. Patients with unresectable locally advanced or metastatic biliary tract cancer confirmed by histopathology. 5. Failed in the prior one or more standard therapies. 6. HER2 positive (IHC 3 + or IHC 2 +) in the tumor specimens confirmed by central laboratory test. 7. Archival or biopsy tumor specimens should be provided (primary or metastatic). 8. Patients must have measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). 9. ECOG performance score 0 or 1. 10. Prior anti-tumor treatment-related AEs (NCI CTCAE v5.0 Criteria) have recovered to ≤ Grade 1 (except alopecia, non-clinically significant or asymptomatic laboratory abnormalities). 11. No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) ≥ 50%. 12. Organ function must meet the basic requirements. 13. Coagulation function must meet the basic requirements. 14. Patients of childbearing potential must take effective contraceptive measures during the treatment and for 6 months after the last dose of treatment.
Exclusion criteria
1. History of hypersensitivity to any component of MRG002 or history of hypersensitivity of ≥ Grade 3 to trastuzumab. 2. Received chemotherapy, radiotherapy, biologicals, immunotherapy, or other anti-tumor drugs within 4 weeks prior to the first MRG002 treatment. 3. Presence of clinical manifestation of biliary obstruction. 4. Patients with clinical symptoms such as pleural, abdominal or pericardial effusion requiring puncture drainage. 5. Presence of central nervous system (CNS) metastasis and/or neoplastic meningitis. 6. Any severe or uncontrolled systemic diseases. 7. Patients with poorly controlled heart diseases. 8. Evidence of active infections, including but not limited to Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) infection. 9. History of other primary malignancies. 10. History of interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc. 11. Peripheral neuropathy greater than Grade 1. 12. History of cirrhosis (decompensated cirrhosis Child-Pugh class B and C). 13. Patients with active autoimmune disease or a history of autoimmune disease, who are using immunosuppressive agents, or systemic hormone therapy and still receiving within 2 weeks prior to enrollment. 14. Received anti-tumor vaccine treatment 4 weeks prior to the first dose or planning to participate in anti-tumor vaccine trials. 15. Female patents with a positive serum pregnancy test or who are breast-feeding or who do not agree to take adequate contraceptive measures during the treatment and for 6 months after the last dose of study treatment. 16. Other conditions inappropriate for participation in this clinical trial, at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) by Independent Review Committee (IRC) | Baseline to study completion, up to 12 months | ORR is defined as the percentage of patients with a complete response (CR) and partial response (PR) as assessed by Independent Review Committee (IRC) according to RECIST v1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Response (DoR) | Baseline to study completion, up to 12 months | DOR is defined as the time from first documented objective response to the first onset of tumor progression or death of any cause. |
| Time to Response (TTR) | Baseline to study completion, up to 12 months | TTR is defined as the duration from the start of treatment to the first onset of CR or PR in tumor evaluation. |
| Disease Control Rate (DCR) | Baseline to study completion, up to 12 months | DCR is defined as the percentage of patients who achieve CR, PR, and stable disease (SD) after treatment. |
| Progression Free Survival (PFS) | Baseline to study completion, up to 12 months | PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause. |
| ORR by Investigator | Baseline to study completion, up to 12 months | ORR is defined as the percentage of patients with a CR and PR as assessed by Investigator according to RECIST v1.1. |
| Adverse Events (AEs) | Baseline to 30 days after the last dose of study treatment | Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug. |
| Pharmacokinetics (PK) Parameter of MRG002: concentration-time curve | Baseline to 30 days after the last dose of study treatment | Concentration-time curve will be depicted based on pharmacokinetics concentration set (PKCS). |
| Incidence of anti-drug antibody (ADA) | Baseline to 30 days after the last dose of study treatment | The incidence of ADA analysis will be summarized for all patients who received at least one cycle study treatment. |
| Overall Survival (OS) | Baseline to study completion, up to 12 months | OS is defined as the duration from the start of treatment to death of any cause. |
Countries
China
Contacts
Primary ContactProgram Director
Outcome results
None listed